3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neoplasms
14
Pain
13
Pain, Postoperative
12
Cancer Pain
10
Agnosia
7
Chronic Pain
6
Colorectal Neoplasms
4
Colonic Neoplasms
4
Breast Neoplasms
4
Neoplasm Metastasis
3
Mucositis
3
Lung Neoplasms
3
Head and Neck Neoplasms
3
Supratentorial Neoplasms
2
Pancreatic Neoplasms
2
Pain, Intractable
2
Neoplastic Cells, Circulating
2
Multiple Myeloma
2
Lymphoma
2
Leukemia, Myeloid, Acute
2
Leukemia, Biphenotypic, Acute
2
Leukemia
2
Inflammation
2
Ileus
2
Hematologic Neoplasms
2
Wounds and Injuries
1
Waldenstrom Macroglobulinemia
1
Vesico-Ureteral Reflux
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Interventions
Docetaxel
171
Radiotherapy
144
Magnetic Resonance Spectroscopy
142
Leuprolide
112
Prednisone
108
enzalutamide
102
Radiosurgery
101
Abiraterone Acetate
94
Androgen Antagonists
91
Goserelin
83
bicalutamide
81
gallium 68 PSMA-11
70
Surveys and Questionnaires
63
apalutamide
57
Specimen Handling
56
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
55
Radiation
47
Gonadotropin-Releasing Hormone
45
Standard of Care
44
Biopsy
44
Brachytherapy
42
Radiotherapy, Intensity-Modulated
40
Blood Specimen Collection
40
darolutamide
39
abiraterone
39
cabazitaxel
35
Exercise
35
Carboplatin
33
Pluvicto
32
Triptorelin Pamoate
31
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Prostatic Neoplasms
×
Morphine
×
Clear all
NCT01367418
2012-03-19
AIMS
Örebro University, Sweden
Phase 3
Completed
26 enrolled